AbCellera Biologics has a Cash Ratio of 8.17. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for AbCellera Biologics's Cash Ratio or its related term are showing as below:
ABCL'
s Cash Ratio Range Over the Past 10 Years
Min: 0.96 Med: 5.99 Max: 8.17
Current: 8.17
During the past 7 years, AbCellera Biologics's highest Cash Ratio was 8.17. The lowest was 0.96. And the median was 5.99.
ABCL's Cash Ratio is ranked better than 78.01% of 1469
companies
in the Biotechnology industry
Industry Median: 2.71
vs ABCL: 8.17
AbCellera Biologics Cash Ratio Historical Data
The historical data trend for AbCellera Biologics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AbCellera Biologics's Cash Ratio
For the Biotechnology subindustry, AbCellera Biologics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (NAS:ABCL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
AbCellera Biologics Cash Ratio Related Terms
Thank you for viewing the detailed overview of AbCellera Biologics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABCL has been successfully added to your 